PT Kalbe Farma Tbk · IDX:KLBF

PT Kalbe Farma Tbk — 9M 2024 Earnings Presentation

49 slides from PT Kalbe Farma Tbk's earnings presentation, October 2024

  1. Slide 1: Company Update 9M24

    Company Update 9M24 PT Kalbe Farma Tbk October 2024

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2024 unaudited results of the Company. The information co

  3. Slide 3: Table of Content

    Table of Content • Key Updates 04 • Key Business Strategies 07 • Financial Overview 24 • Appendix 1 31 • Appendix 2 38

  4. Slide 4: Key Updates

    y Key Updates

  5. Slide 5: Broad-based Growth with Emphasis on Higher Growth Categories

    Broad-based Growth with Emphasis on Higher Growth Categories 2024 Key Strategies Market International Pharmaceuticals Prescription Devices Medical Consumer NutritionalsHealth Distribution Logistics Prescription Medical International Consumer Health Distribution Pharmaceuticals Devices Market & Nutri

  6. Slide 6: Solid Foundation for Future Growth

    Solid Foundation for Future Growth Key Takeaways Strategic Partnerships and Investments 15.7% 9M24 Net 9M24 EPS 7.4% Sales growth 15.7% growth New Product Development Strategic Partnership with Alliance Pharma Co.,Ltd. (Thailand) Key Updates Zerpidio and Efesa have Radiopharmaceuticals Key Risks bee

  7. Slide 7: Business Strategies

    y Business Strategies

  8. Slide 8: More than Half a Century of Providing Wide-Range Healthcare Solutions

    More than Half a Century of Providing Wide-Range Healthcare Solutions Corporate Overview Market Capitalization The largest publicly-listed pharmaceuticals company in Southeast Asia IDR 80.9 tn ($5.3 bn)* Onwards 1966 1991 free float Established, headquartered The most integrated * Listed in the Indo

  9. Slide 9: Positive Net Sales Growth Post-Pandemic

    Positive Net Sales Growth Post-Pandemic Prescription Pharmaceuticals Building Participation in Dominant Specialty Portfolio National Health Insurance Market Leader Steadily growing specialty Consistent growth Leading with 13% category with in E-Catalog market share expanding innovative portfolio, su

  10. Slide 10: Driving Future Growth through Strategic Collaborations

    Driving Future Growth through Strategic Collaborations Prescription Pharmaceuticals Sustaining Business Expansion through Strategic Partnerships Oncology Livzon Pharma Indonesia Shareholder Agreement Signing Jul 2024 To locally manufacture more advanced pharmaceuticals ingredients for the export mar

  11. Slide 11: Innovative Biologics Products

    Innovative Biologics Products Prescription Pharmaceuticals: Specialty Category Approved Novel Biologics Strengthening Portfolio in Zerpidio (HLX10 – Serplulimab) Oncology • Approved in Dec 2023, commercialization in 2024 • Approved by local FDA in Thailand Serplulimab (Zerpidio 100 mg) Signing cerem

  12. Slide 12: Positive Net Sales Growth Post-Pandemic

    Positive Net Sales Growth Post-Pandemic Prescription Pharmaceuticals 10.4% 28.4% Net Sales growth - 9M24 Contribution From Rp6,246 bn to 6,896 bn to total net sales Kalbe Unbranded 13% Licensed generics 51.6% 27% 27% a 9% Gross Profit Margin - 9M24 Contribution Market Share b 6% • Decreased from 52.

  13. Slide 13: Market Recovery Post-Covid Normalization

    Market Recovery Post-Covid Normalization Consumer Health Strong Dominant Driving Customer Base Market Position Product Innovation Solid customer base in OTC Leading with 10% market Expanding to preventive and health supplement share categories as future growth with strong brand loyalty driver

  14. Slide 14: Expanding into Preventive and Wellness Category

    Expanding into Preventive and Wellness Category Consumer Health Our Market Share Driving product innovation and new product launches in potential categories Strong Customer Loyalty 72% 46% Antacids Anti Diarrhea (Promag) (Entrostop) 50% 39% Entrostop Komix Woods Mixagrip Procold Sakatonik ABC Promag

  15. Slide 15: Market Recovery Post-Covid Normalization

    Market Recovery Post-Covid Normalization Consumer Health 4.0% 13.6% Net Sales growth - 9M24 Contribution From Rp3,160 bn to 3,285 bn to total net sales Health Supplement 60.8% 28% Gross Profit Margin - 9M24 Contribution Market Share • Increased from 59.0% in 9M23 due to lower raw material price • AS

  16. Slide 16: Maintaining Top-line Growth in a Challenging Market

    Maintaining Top-line Growth in a Challenging Market Nutritionals Extensive Strengthening Strong Product Portfolio Market Share Product Innovation Complete product offering Dominant local player with Expanding to for all life stages and 15% market share affordable and ready- functional products to-dr

  17. Slide 17: Expanding to Affordable and Ready-to-Drink Products

    Expanding to Affordable and Ready-to-Drink Products Nutritionals Performs above the market New product launches Extensive Portfolio to Serve All Ages and Segments Expecting Mothers Lactating Mothers Kids Teens Adults Senior Clinical -3.1% Powdered Milk Market Nielsen 9M24 new new new new new 10 - 15

  18. Slide 18: Maintaining Top-line Growth in a Challenging Market

    Maintaining Top-line Growth in a Challenging Market Nutritionals 0.2% 25.5% Net Sales growth - 9M24 Contribution From Rp6,167 bn to 6,178 bn to total net sales f others Kalbe Specialty e 4% 3% 15% 14% 7% d 51.3% 4% Gross Profit Margin - 9M24 Adults Contribution c 15% Market Share a • Increased from

  19. Slide 19: Positive Acceptance in Export Countries

    Positive Acceptance in Export Countries International Business Pharmaceuticals Highlights Temporary weakness driven by country specific issues such as political instability, restriction of import license and weaker consumer purchasing power Consumer Health 9M24 Nutritionals unaudited Net Sales Growt

  20. Slide 20: The Largest Distribution Network in Healthcare, Supported by Digital Expansion

    The Largest Distribution Network in Healthcare, Supported by Digital Expansion Distribution and Logistics Best-in-class pharma Leveraging Medical Device as new distribution digitalization growth driver Robust multi-channels network through EMOS and Shifting to local production with presence in 71 br

  21. Slide 21: Widest Network in Pharmaceuticals Distribution

    Widest Network in Pharmaceuticals Distribution Distribution & Logistics Major Third-Party Principals Prescription Pharmaceuticals Consumer +200K Outlets +200K 71 Branches Medical Instrument & Diagnostic Fine Chemical Raw Materials 3 3 Expanding to Cold-Chain Distribution Business Regional Distributi

  22. Slide 22: Moving Towards Local Manufacturing/Assembly

    Moving Towards Local Manufacturing/Assembly Distribution & Logistics: Medical Devices • Accelerate technology transfer to build local Established Surgical Suture, Mobile X-ray, and Dialyzer Facility manufacturing capabilities • Meet the local content requirements for JKN Program Consumables Surgical

  23. Slide 23: The Largest Distribution Network in Healthcare, Supported by Digital Expansion

    The Largest Distribution Network in Healthcare, Supported by Digital Expansion Distribution and Logistics 12.8% 32.5% Medical Devices Raw Materials • Managed by PT Enseval Putera Trading Net Sales growth - 9M24 Contribution 5% 8% Megatrading Tbk (EPMT IJ), a From Rp6,988 bn to 7,879 bn to total net

  24. Slide 24: Financial Overview

    y Financial Overview

  25. Slide 25: Sustained Top-line Recovery

    Sustained Top-line Recovery Consolidated Operational Performance Net Sales 7.4% In IDR bn (unaudited) 24,239 22,561 10.4% 4.0% 0.2% 12.8% 7,879 6,246 6,896 6,167 6,178 6,988 3,160 3,285 Prescription Consumer Health Nutritionals Distribution & Logistics Total Consolidated Pharmaceuticals Net Sales Se

  26. Slide 26: Sustained Margin Improvement Trend

    Sustained Margin Improvement Trend Consolidated Operational Performance Gross Profit Operating Expenses to Net Sales Net Income 6.9% 15.2% 27.4% 26.9% 9.2% 9.8% 39.5% 39.3% 1.2% 1.3% 5.0% 4.8% R&D Expenses G&A Expenses Selling Expenses 9,517 21.2% 20.8% 2,378 8,903 2,065 Sep 23 Sep 24 Sep 23 Sep 24

  27. Slide 27: Securing Product Quality and Availability by Managing Inventory

    Securing Product Quality and Availability by Managing Inventory Working Capital Management 180 162 Managing Net Operating Cycle 160 154 139 • Inventory level has gradually moderated on 140 129 120 147 track to normalization 120 131 • Consistently managing supply chain challenges and 122 119 100 ensu

  28. Slide 28: Healthy Cash Balance to Support Operation and Business Expansion

    Healthy Cash Balance to Support Operation and Business Expansion Capital Allocation Total Debt & Gearing Ratio Cash & Cash Equivalent 5.1% 6,216 1,200 5.8% 7.0% 8.0% 5,590 5,208 1,000 6.0% 6.0% 4,050 4,174 800 3,950 3,232 3,583 2.6% 2.5% 2.5% 5.0% 2,833 600 4.0% 2,656 1,067 1,116 400 4.0% 560 577 59

  29. Slide 29: Improving Financial Results

    Improving Financial Results Financial Strategies 2024 Sustaining top line growth through organic and inorganic opportunities Driving margin improvement through continuous efficiency in production process, marketing effectiveness and leveraging digitalization Forex cash reserve to mitigate exchange r

  30. Slide 30: Focusing on Top and Bottom-Line Improvement

    Focusing on Top and Bottom-Line Improvement Outlook 2024 Growing above the market & Consistently optimizing commercializing new Improving profitability shareholders' return innovative products YoY Sales Growth EPS Growth Dividend Payout 6 to 7% 13% to 15% Ratio 45 to 55% 9M24 : 7.4% 9M24 : 15.7% Ass

  31. Slide 31: Appendix 1

    y Appendix 1

  32. Slide 32: Sustained Top-line Growth and Resilient Margins Over a Decade

    Sustained Top-line Growth and Resilient Margins Over a Decade Key Takeaways 16,367 15,731 • Sustained consolidated top-line growth at CAGR 5.8% over 14,567 15,227 15,144 a decade. 12,226 • Resilient margins (Operating Profit Margin at 14%-15% in 2014-2022) reflecting a well-managed operational Gross

  33. Slide 33: Relatively Stable Macroeconomy with Changes in Consumer Spending Post Covid

    Relatively Stable Macroeconomy with Changes in Consumer Spending Post Covid Market Overview Indonesia Macroeconomics • Stable and positive key macroeconomic indicators due to higher mobility post Covid • Managing risks of high inflation, decreasing purchasing power, customers spending allocation tre

  34. Slide 34: Growing National Health Insurance Coverage and Increasing Health Budget

    Growing National Health Insurance Coverage and Increasing Health Budget Healthcare Industry Overview Population In million National Health Insurance (JKN) Coverage 300 61.0% 66.1% 71.6% 78.5% 83.9% 82.3% 86.1% 90.7% 95.2% 98.2% 120% 250 100% 200 80% 150 273.9 274.2 280.7 281.6* 60% 257.2 260.0 262.4

  35. Slide 35: Ensuring Compliance and Support to Government Strategic Programs

    Ensuring Compliance and Support to Government Strategic Programs Recent Pharma Regulations Presidential Decree No. 28/2024 • Implementing Law No 17 of 2023 concerning healthcare regulation. Law No. 17/2023 • Healthcare regulation for future growth. Government Regulation No. 46/2023 • Ease of importi

  36. Slide 36: Access to Healthcare for a Better Life

    Access to Healthcare for a Better Life Gradual Improvement of ESG Practices Based on International Standard Environment Energy efficiency and CO2 emission reduction Gradually moving towards energy efficiency and CO2 emission reduction through renewable energy by E installing solar panels in our new

  37. Slide 37: Sustainability Activities

    Sustainability Activities Improving Access to Healthcare and Implementing Responsible Business Practices Ristek/BRIN Kalbe Science Award (RKSA) 2021-2023 RKSA is the collaboration between Ristek/BRIN (2021) and KALBE in strengthening triple helix collaboration between academics, business and governm

  38. Slide 38: Appendix 2

    y Appendix 2

  39. Slide 39: Financial Statement

    Financial Statement CONSOLIDATED STATEMENT Dec 23 Sep 24 Change YTD OF FINANCIAL POSITION (Audited) (Unaudited) ASSETS CURRENT ASSETS Cash and Cash Equivalents 3,232,420,596,769 4,174,378,727,489 29.1% Trade Receivables 4,651,970,696,489 5,000,880,323,609 7.5% Other Receivables 168,170,214,069 189,2

  40. Slide 40: Financial Statement

    Financial Statement CONSOLIDATED STATEMENT Dec 23 Sep 24 Change YTD OF FINANCIAL POSITION (Audited) (Unaudited) LIABILITIES CURRENT LIABILITIES Short-term Bank Loans 120,800,000,000 318,600,000,000 163.7% Trade Payables 1,690,719,605,626 1,946,533,074,824 15.1% Other Payables 548,228,291,405 729,335

  41. Slide 41: Financial Statement

    Financial Statement CONSOLIDATED STATEMENT Dec 23 Sep 24 Change YTD OF FINANCIAL POSITION (Audited) (Unaudited) EQUITY Capital Stock - Issued and Fully Paid 468,751,221,100 468,751,221,100 0.0% Additional Paid-in Capital, Net (34,118,673,814) (33,093,373,814) -3.0% Differences Arising from Transacti

  42. Slide 42: Financial Statement

    Financial Statement CONSOLIDATED STATEMENT OF PROFIT OR LOSS Sep 23 Sep 24 Change yoy AND OTHER COMPREHENSIVE INCOME (Unaudited) (Unaudited) NET SALES 22,561,006,413,774 24,238,762,731,250 7.4% COST OF GOODS SOLD (13,658,036,825,593) (14,721,787,709,511) 7.8% GROSS PROFIT 8,902,969,588,181 9,516,975

  43. Slide 43: Financial Statement

    Financial Statement CONSOLIDATED STATEMENT OF PROFIT OR LOSS Sep 23 Sep 24 Change yoy AND OTHER COMPREHENSIVE INCOME (Unaudited) (Unaudited) INCOME BEFORE INCOME TAX EXPENSE 2,651,081,206,362 3,092,039,705,830 16.6% % to NS 11.8% 12.8% INCOME TAX EXPENSE (577,784,847,033) (695,705,504,166) 20.4% % t

  44. Slide 44: Financial Statement

    Financial Statement CONSOLIDATED STATEMENT OF PROFIT OR LOSS Sep 23 Sep 24 Change yoy AND OTHER COMPREHENSIVE INCOME (Unaudited) (Unaudited) Income (Loss) for the Period Attributable to: Owners of the Parent Company 2,064,925,608,770 2,378,379,096,789 15.2% % to NS 9.2% 9.8% Total 2,073,296,359,329

  45. Slide 45: Financial Statement

    Financial Statement Sep 23 Sep 24 CONSOLIDATED STATEMENT OF CASH FLOWS Change YoY (Unaudited) (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES Cash received from customers 24,472,365,331,335 26,650,276,155,176 8.9% Cash payments to suppliers and employees (16,912,110,982,654) (17,347,317,045,037) -2

  46. Slide 46: Financial Statement

    Financial Statement Sep 23 Sep 24 CONSOLIDATED STATEMENT OF CASH FLOWS Change YoY (Unaudited) (Unaudited) CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of investment in associate 71,085,198,069 - Interest income received 50,997,296,404 101,029,782,807 98.1% Withdrawal of other current fina

  47. Slide 47: Financial Statement

    Financial Statement Sep 23 Sep 24 CONSOLIDATED STATEMENT OF CASH FLOWS Change YoY (Unaudited) (Unaudited) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from bonds payables - 126,368,000,000 Payments of interest expenses (74,160,387,512) (46,850,181,991) 36.8% Proceeds from short-term bank loans 1,74

  48. Slide 48: Financial Statement

    Financial Statement Sep 23 Sep 24 CONSOLIDATED STATEMENT OF CASH FLOWS Change YoY (Unaudited) (Unaudited) NET INCREASE (DECREASE) IN CASH (1,322,613,977,148) 968,869,081,093 173.3% AND CASH EQUIVALENTS Net Effect of Changes in Foreign Exchange Rates of Foreign Currency Denominated Cash and Cash Equi

  49. Slide 49: For further information

    For further information : PT Kalbe Farma Tbk | Jalan Let. Jend. Suprapto Kav. 4 | Jakarta 10510, Indonesia Tel. : 62-21-42873888 | Fax. : 62-21-42873678 Email : syeren.amanda@kalbecorp.com investor.relations@kalbecorp.com

PT Kalbe Farma — 9M 2024 Earnings Presentation on 6ix